IBDEI0QD ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13010,2)
 ;;=^124214
 ;;^UTILITY(U,$J,358.3,13011,0)
 ;;=079.99^^87^828^41
 ;;^UTILITY(U,$J,358.3,13011,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13011,1,4,0)
 ;;=4^079.99
 ;;^UTILITY(U,$J,358.3,13011,1,5,0)
 ;;=5^Viral Syndrome
 ;;^UTILITY(U,$J,358.3,13011,2)
 ;;=^295798
 ;;^UTILITY(U,$J,358.3,13012,0)
 ;;=131.01^^87^828^40
 ;;^UTILITY(U,$J,358.3,13012,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13012,1,4,0)
 ;;=4^131.01
 ;;^UTILITY(U,$J,358.3,13012,1,5,0)
 ;;=5^Vaginitis, Trichomonas
 ;;^UTILITY(U,$J,358.3,13012,2)
 ;;=^121763
 ;;^UTILITY(U,$J,358.3,13013,0)
 ;;=070.1^^87^828^12
 ;;^UTILITY(U,$J,358.3,13013,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13013,1,4,0)
 ;;=4^070.1
 ;;^UTILITY(U,$J,358.3,13013,1,5,0)
 ;;=5^Hepatitis A 
 ;;^UTILITY(U,$J,358.3,13013,2)
 ;;=^126486
 ;;^UTILITY(U,$J,358.3,13014,0)
 ;;=070.30^^87^828^13
 ;;^UTILITY(U,$J,358.3,13014,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13014,1,4,0)
 ;;=4^070.30
 ;;^UTILITY(U,$J,358.3,13014,1,5,0)
 ;;=5^Hepatitis B, Acute
 ;;^UTILITY(U,$J,358.3,13014,2)
 ;;=^266626
 ;;^UTILITY(U,$J,358.3,13015,0)
 ;;=070.32^^87^828^14
 ;;^UTILITY(U,$J,358.3,13015,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13015,1,4,0)
 ;;=4^070.32
 ;;^UTILITY(U,$J,358.3,13015,1,5,0)
 ;;=5^Hepatitis B, Chronic
 ;;^UTILITY(U,$J,358.3,13015,2)
 ;;=^303249
 ;;^UTILITY(U,$J,358.3,13016,0)
 ;;=070.51^^87^828^15
 ;;^UTILITY(U,$J,358.3,13016,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13016,1,4,0)
 ;;=4^070.51
 ;;^UTILITY(U,$J,358.3,13016,1,5,0)
 ;;=5^Hepatitis C Acute
 ;;^UTILITY(U,$J,358.3,13016,2)
 ;;=^266632
 ;;^UTILITY(U,$J,358.3,13017,0)
 ;;=042.^^87^828^11
 ;;^UTILITY(U,$J,358.3,13017,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13017,1,4,0)
 ;;=4^042.
 ;;^UTILITY(U,$J,358.3,13017,1,5,0)
 ;;=5^HIV Disease (symptomatic)
 ;;^UTILITY(U,$J,358.3,13017,2)
 ;;=HIV Disease (symptomatic)^266500
 ;;^UTILITY(U,$J,358.3,13018,0)
 ;;=054.12^^87^828^20
 ;;^UTILITY(U,$J,358.3,13018,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13018,1,4,0)
 ;;=4^054.12
 ;;^UTILITY(U,$J,358.3,13018,1,5,0)
 ;;=5^Herpetic Infect of Vulva
 ;;^UTILITY(U,$J,358.3,13018,2)
 ;;=^266559
 ;;^UTILITY(U,$J,358.3,13019,0)
 ;;=795.51^^87^828^36
 ;;^UTILITY(U,$J,358.3,13019,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13019,1,4,0)
 ;;=4^795.51
 ;;^UTILITY(U,$J,358.3,13019,1,5,0)
 ;;=5^Tuberculosis Skin Test Pos W/O Active TB
 ;;^UTILITY(U,$J,358.3,13019,2)
 ;;=^340572
 ;;^UTILITY(U,$J,358.3,13020,0)
 ;;=097.1^^87^828^29
 ;;^UTILITY(U,$J,358.3,13020,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13020,1,4,0)
 ;;=4^097.1
 ;;^UTILITY(U,$J,358.3,13020,1,5,0)
 ;;=5^Syphilis,Latent
 ;;^UTILITY(U,$J,358.3,13020,2)
 ;;=^116843
 ;;^UTILITY(U,$J,358.3,13021,0)
 ;;=054.9^^87^828^17
 ;;^UTILITY(U,$J,358.3,13021,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13021,1,4,0)
 ;;=4^054.9
 ;;^UTILITY(U,$J,358.3,13021,1,5,0)
 ;;=5^Herpes Simplex,Mouth/Lip
 ;;^UTILITY(U,$J,358.3,13021,2)
 ;;=^56902
 ;;^UTILITY(U,$J,358.3,13022,0)
 ;;=112.84^^87^828^1
 ;;^UTILITY(U,$J,358.3,13022,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13022,1,4,0)
 ;;=4^112.84
 ;;^UTILITY(U,$J,358.3,13022,1,5,0)
 ;;=5^Candidiasis Esophagitis
 ;;^UTILITY(U,$J,358.3,13022,2)
 ;;=^259729
 ;;^UTILITY(U,$J,358.3,13023,0)
 ;;=112.0^^87^828^2
 ;;^UTILITY(U,$J,358.3,13023,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13023,1,4,0)
 ;;=4^112.0
 ;;^UTILITY(U,$J,358.3,13023,1,5,0)
 ;;=5^Candidiasis,Oral
 ;;^UTILITY(U,$J,358.3,13023,2)
 ;;=^18599
 ;;^UTILITY(U,$J,358.3,13024,0)
 ;;=070.54^^87^828^16
 ;;^UTILITY(U,$J,358.3,13024,1,0)
 ;;=^358.31IA^5^2
